Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Dow
Mallinckrodt
Moodys
Johnson and Johnson

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,772,178

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 7,772,178 protect, and when does it expire?

Patent 7,772,178 protects VICTRELIS and is included in one NDA.

This patent has nineteen patent family members in sixteen countries.

Summary for Patent: 7,772,178
Title:Pharmaceutical formulations and methods of treatment using the same
Abstract:Pharmaceutical formulations containing at least one compound of Formulae I-XXVI herein and at least one surfactant. Pharmaceutically acceptable carriers and excipients may also be included in the formulations. The formulations of the present invention are suited for use in single unit dosages.
Inventor(s): Malcolm; Bruce A. (Paoli, PA), Bradley; Prudence K. (Cranford, NJ), Pavlovsky; Anastasia (Morris Plains, NJ), Cho; Wing-Kee Philip (Princeton, NJ), Qiu; Zhihui (Bridgewater, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:11/444,078
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Use; Composition;

Drugs Protected by US Patent 7,772,178

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Merck Sharp Dohme VICTRELIS boceprevir CAPSULE;ORAL 202258-001 May 13, 2011 DISCN No No   Start Trial   Start Trial Y TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,772,178

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 055198   Start Trial
Australia 2006252553   Start Trial
Brazil PI0610737   Start Trial
Canada 2611155   Start Trial
China 101212970   Start Trial
European Patent Office 1919478   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Baxter
Johnson and Johnson
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.